Literature DB >> 23858346

Photoletter to the editor - Calciphylaxis: a diagnostic and therapeutic challenge.

Hugo Marques Barreiros1, João Goulão, Henriqueta Cunha, Elvira Bártolo.   

Abstract

Calciphylaxis is an uncommon necrotizing dermal condition, most often related to end-stage renal disease, associated with secondary hyperparathyroidism. The incidence is 1-4% per year in dialyzed patients. The condition is characterized by microcalcification of small and medium-sized blood vessels, causing cutaneous and soft tissue necrosis. The etiology of calciphylaxis is poorly understood, although many reports highlight the abnormal calcium-phosphate products as an important etiological factor. Calciphylaxis is associated with significant morbidity and mortality with estimated 5-year survival rates of less than 50%. Sepsis is the main cause of death. We report two patients of calciphylaxis treated with surgical debridement and excellent outcome in both cases.

Entities:  

Keywords:  calciphylaxis; calcium; kidney failure; surgical debridement; treatment; ulcer

Year:  2013        PMID: 23858346      PMCID: PMC3710683          DOI: 10.3315/jdcr.2013.1136

Source DB:  PubMed          Journal:  J Dermatol Case Rep        ISSN: 1898-7249


  4 in total

1.  A rare cause of ulceration with a promising new treatment. Calciphylaxis due to secondary hyperparathyroidism caused by vitamin D deficiency.

Authors:  D S Shah; D J Williamson
Journal:  Clin Exp Dermatol       Date:  2010-04       Impact factor: 3.470

2.  Is calciphylaxis best treated surgically or medically?

Authors:  A S Kang; J T McCarthy; C Rowland; D R Farley; J A van Heerden
Journal:  Surgery       Date:  2000-12       Impact factor: 3.982

3.  Calciphylaxis in patients on hemodialysis: a prevalence study.

Authors:  M Angelis; L L Wong; S A Myers; L M Wong
Journal:  Surgery       Date:  1997-12       Impact factor: 3.982

Review 4.  Mysterious calciphylaxis: wounds with eschar--to debride or not to debride?

Authors:  Rosalia Martin
Journal:  Ostomy Wound Manage       Date:  2004-04       Impact factor: 2.629

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.